We are analyzing https://link.springer.com/article/10.1007/s40262-018-0703-0.

Title:
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib | Clinical Pharmacokinetics
Description:
Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor), for unresectable or metastatic BRAF-mutated melanoma, advanced non-small cell lung cancer and anaplastic thyroid cancer harbouring the BRAFV600E mutation. The recommended dose of dabrafenib is 150 mg twice daily (bid) under fasted conditions. After single oral administration of the recommended dose, the absolute oral bioavailability (F) of dabrafenib is 95%. Dabrafenib shows a time-dependent increase in apparent clearance (CL/F) following multiple doses, which is likely due to induction of its own metabolism through cytochrome P450 (CYP) 3A4. Therefore, steady state is reached only after 14 days of daily dose administration. Moreover, the extent of this auto-induction process is dependent on the dose, which explains why dabrafenib systemic exposure at steady state increases less than dose proportionally over the dose range of 75–300 mg bid. The main elimination route of dabrafenib is the oxidative metabolism via CYP3A4/2C8 and biliary excretion. Among the three major metabolites identified, hydroxy-dabrafenib appears to contribute to the pharmacological activity. Age, sex and body weight did not have any clinically significant influence on plasma exposure to dabrafenib. No dose adjustment is needed for patients with mild renal or hepatic impairment, whereas the impacts of severe impairment on dabrafenib pharmacokinetics remain unknown. Considering that dabrafenib is a substrate of CYP3A4/2C8 and is a CYP3A4/2B6/2C inducer, drug–drug interactions are expected with dabrafenib. The relationship between clinical outcomes and plasma exposure to dabrafenib and hydroxy-dabrafenib should be investigated more deeply.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

pubmed, article, google, scholar, dabrafenib, cas, melanoma, braf, central, cancer, patients, trametinib, metastatic, clin, pharmacokinetics, phase, drug, oncol, inhibitor, clinical, cell, long, dose, trial, lancet, inhibitors, france, combination, audrey, raf, paris, benoit, blanchet, kinase, med, pharmacol, mek, access, therapy, treatment, accessed, multicentre, openlabel, flaherty, combined, ther, engl, brain, toulouse, privacy,

Topics {✒️}

eu/docs/en_gb/document_library/epar_-_product_information/human/002604/wc500149671 eu/docs/en_gb/document_library/epar_-_public_assessment_report/human/002604/wc500149673 threonine-protein kinase b-raf braf-mutated high-grade glioma month download article/chapter gov/downloads/drugs/guidances/ucm070246 b-raf-driven tumors braf mutation-positive tumors val600 braf-mutant melanoma braf v600-mutant tumours p450-mediated ddi risk small-cell lung cancer carbon-carbon bond cleavage gov/drugsatfda_docs/nda/2013/202806orig1s000clinpharmr mitogen-activated protein kinase gov/ct2/show/nct02873650 metastatic braf-mutated melanoma braf-mutated metastatic melanoma cyp3a4/2b6/2c inducer benoit blanchet declare braf v600e mutation gov/drugsatfda_docs/label/2018/202806s010lbl trametinib combination therapy marie-noëlle paludetto drug–drug interactions audrey thomas-schoemann wild-type braf mapk-activated protein kinases braf-mutant kinase article puszkiel davies ma etienne chatelut full article pdf combination therapy braf v600 mutations privacy choices/manage cookies drug metab dispos therapeutic drug monitoring drug monitoring unit benoit blanchet dabrafenib-treated melanoma patients health-related quality braf-mutated melanoma raf inhibitors activate falchook gs untreated brain metastases braf inhibitors equal drug interaction potential mol cancer ther pharmacokinetic profile

Questions {❓}

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
         description:Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor), for unresectable or metastatic BRAF-mutated melanoma, advanced non-small cell lung cancer and anaplastic thyroid cancer harbouring the BRAFV600E mutation. The recommended dose of dabrafenib is 150 mg twice daily (bid) under fasted conditions. After single oral administration of the recommended dose, the absolute oral bioavailability (F) of dabrafenib is 95%. Dabrafenib shows a time-dependent increase in apparent clearance (CL/F) following multiple doses, which is likely due to induction of its own metabolism through cytochrome P450 (CYP) 3A4. Therefore, steady state is reached only after 14 days of daily dose administration. Moreover, the extent of this auto-induction process is dependent on the dose, which explains why dabrafenib systemic exposure at steady state increases less than dose proportionally over the dose range of 75–300 mg bid. The main elimination route of dabrafenib is the oxidative metabolism via CYP3A4/2C8 and biliary excretion. Among the three major metabolites identified, hydroxy-dabrafenib appears to contribute to the pharmacological activity. Age, sex and body weight did not have any clinically significant influence on plasma exposure to dabrafenib. No dose adjustment is needed for patients with mild renal or hepatic impairment, whereas the impacts of severe impairment on dabrafenib pharmacokinetics remain unknown. Considering that dabrafenib is a substrate of CYP3A4/2C8 and is a CYP3A4/2B6/2C inducer, drug–drug interactions are expected with dabrafenib. The relationship between clinical outcomes and plasma exposure to dabrafenib and hydroxy-dabrafenib should be investigated more deeply.
         datePublished:2018-08-09T00:00:00Z
         dateModified:2018-08-09T00:00:00Z
         pageStart:451
         pageEnd:467
         sameAs:https://doi.org/10.1007/s40262-018-0703-0
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig4_HTML.png
         isPartOf:
            name:Clinical Pharmacokinetics
            issn:
               1179-1926
               0312-5963
            volumeNumber:58
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Alicja Puszkiel
               affiliation:
                     name:Université Paul Sabatier
                     address:
                        name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gaëlle Noé
               affiliation:
                     name:Bicetre Hospital, AP-HP
                     address:
                        name:Department of Pharmacology and Toxicology, Bicetre Hospital, AP-HP, Kremlin Bicetre, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Audrey Bellesoeur
               affiliation:
                     name:CERIA, CARPEM, Cochin University Hospital, APHP
                     address:
                        name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                     address:
                        name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nora Kramkimel
               affiliation:
                     name:Cochin University Hospital, AP-HP
                     address:
                        name:Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marie-Noëlle Paludetto
               affiliation:
                     name:Université Paul Sabatier
                     address:
                        name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
                        type:PostalAddress
                     type:Organization
                     name:Institut Universitaire du Cancer de Toulouse - Oncopole
                     address:
                        name:Department of Pharmacy, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Audrey Thomas-Schoemann
               affiliation:
                     name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                     address:
                        name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:University Paris Descartes, PRES Sorbonne Paris Cité
                     address:
                        name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michel Vidal
               affiliation:
                     name:University Paris Descartes, PRES Sorbonne Paris Cité
                     address:
                        name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                     address:
                        name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:François Goldwasser
               affiliation:
                     name:CERIA, CARPEM, Cochin University Hospital, APHP
                     address:
                        name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Etienne Chatelut
               affiliation:
                     name:Université Paul Sabatier
                     address:
                        name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
                        type:PostalAddress
                     type:Organization
                     name:Institut Universitaire du Cancer de Toulouse - Oncopole
                     address:
                        name:Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
                        type:PostalAddress
                     type:Organization
                     name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
                     address:
                        name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Benoit Blanchet
               affiliation:
                     name:University Paris Descartes, PRES Sorbonne Paris Cité
                     address:
                        name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                     address:
                        name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
                     address:
                        name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
      description:Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor), for unresectable or metastatic BRAF-mutated melanoma, advanced non-small cell lung cancer and anaplastic thyroid cancer harbouring the BRAFV600E mutation. The recommended dose of dabrafenib is 150 mg twice daily (bid) under fasted conditions. After single oral administration of the recommended dose, the absolute oral bioavailability (F) of dabrafenib is 95%. Dabrafenib shows a time-dependent increase in apparent clearance (CL/F) following multiple doses, which is likely due to induction of its own metabolism through cytochrome P450 (CYP) 3A4. Therefore, steady state is reached only after 14 days of daily dose administration. Moreover, the extent of this auto-induction process is dependent on the dose, which explains why dabrafenib systemic exposure at steady state increases less than dose proportionally over the dose range of 75–300 mg bid. The main elimination route of dabrafenib is the oxidative metabolism via CYP3A4/2C8 and biliary excretion. Among the three major metabolites identified, hydroxy-dabrafenib appears to contribute to the pharmacological activity. Age, sex and body weight did not have any clinically significant influence on plasma exposure to dabrafenib. No dose adjustment is needed for patients with mild renal or hepatic impairment, whereas the impacts of severe impairment on dabrafenib pharmacokinetics remain unknown. Considering that dabrafenib is a substrate of CYP3A4/2C8 and is a CYP3A4/2B6/2C inducer, drug–drug interactions are expected with dabrafenib. The relationship between clinical outcomes and plasma exposure to dabrafenib and hydroxy-dabrafenib should be investigated more deeply.
      datePublished:2018-08-09T00:00:00Z
      dateModified:2018-08-09T00:00:00Z
      pageStart:451
      pageEnd:467
      sameAs:https://doi.org/10.1007/s40262-018-0703-0
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0703-0/MediaObjects/40262_2018_703_Fig4_HTML.png
      isPartOf:
         name:Clinical Pharmacokinetics
         issn:
            1179-1926
            0312-5963
         volumeNumber:58
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Alicja Puszkiel
            affiliation:
                  name:Université Paul Sabatier
                  address:
                     name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gaëlle Noé
            affiliation:
                  name:Bicetre Hospital, AP-HP
                  address:
                     name:Department of Pharmacology and Toxicology, Bicetre Hospital, AP-HP, Kremlin Bicetre, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Audrey Bellesoeur
            affiliation:
                  name:CERIA, CARPEM, Cochin University Hospital, APHP
                  address:
                     name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                  address:
                     name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nora Kramkimel
            affiliation:
                  name:Cochin University Hospital, AP-HP
                  address:
                     name:Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marie-Noëlle Paludetto
            affiliation:
                  name:Université Paul Sabatier
                  address:
                     name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
                     type:PostalAddress
                  type:Organization
                  name:Institut Universitaire du Cancer de Toulouse - Oncopole
                  address:
                     name:Department of Pharmacy, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Audrey Thomas-Schoemann
            affiliation:
                  name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                  address:
                     name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:University Paris Descartes, PRES Sorbonne Paris Cité
                  address:
                     name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michel Vidal
            affiliation:
                  name:University Paris Descartes, PRES Sorbonne Paris Cité
                  address:
                     name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                  address:
                     name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:François Goldwasser
            affiliation:
                  name:CERIA, CARPEM, Cochin University Hospital, APHP
                  address:
                     name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Etienne Chatelut
            affiliation:
                  name:Université Paul Sabatier
                  address:
                     name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
                     type:PostalAddress
                  type:Organization
                  name:Institut Universitaire du Cancer de Toulouse - Oncopole
                  address:
                     name:Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
                     type:PostalAddress
                  type:Organization
                  name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
                  address:
                     name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Benoit Blanchet
            affiliation:
                  name:University Paris Descartes, PRES Sorbonne Paris Cité
                  address:
                     name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:CERIA, CARPEM, Cochin University Hospital, AP-HP
                  address:
                     name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
                  address:
                     name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical Pharmacokinetics
      issn:
         1179-1926
         0312-5963
      volumeNumber:58
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Université Paul Sabatier
      address:
         name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
         type:PostalAddress
      name:Bicetre Hospital, AP-HP
      address:
         name:Department of Pharmacology and Toxicology, Bicetre Hospital, AP-HP, Kremlin Bicetre, France
         type:PostalAddress
      name:CERIA, CARPEM, Cochin University Hospital, APHP
      address:
         name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
         type:PostalAddress
      name:CERIA, CARPEM, Cochin University Hospital, AP-HP
      address:
         name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
         type:PostalAddress
      name:Cochin University Hospital, AP-HP
      address:
         name:Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
         type:PostalAddress
      name:Université Paul Sabatier
      address:
         name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
         type:PostalAddress
      name:Institut Universitaire du Cancer de Toulouse - Oncopole
      address:
         name:Department of Pharmacy, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
         type:PostalAddress
      name:CERIA, CARPEM, Cochin University Hospital, AP-HP
      address:
         name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
         type:PostalAddress
      name:University Paris Descartes, PRES Sorbonne Paris Cité
      address:
         name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
         type:PostalAddress
      name:University Paris Descartes, PRES Sorbonne Paris Cité
      address:
         name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
         type:PostalAddress
      name:CERIA, CARPEM, Cochin University Hospital, AP-HP
      address:
         name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
         type:PostalAddress
      name:CERIA, CARPEM, Cochin University Hospital, APHP
      address:
         name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
         type:PostalAddress
      name:Université Paul Sabatier
      address:
         name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
         type:PostalAddress
      name:Institut Universitaire du Cancer de Toulouse - Oncopole
      address:
         name:Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
         type:PostalAddress
      name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
      address:
         name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
         type:PostalAddress
      name:University Paris Descartes, PRES Sorbonne Paris Cité
      address:
         name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
         type:PostalAddress
      name:CERIA, CARPEM, Cochin University Hospital, AP-HP
      address:
         name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
         type:PostalAddress
      name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
      address:
         name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Alicja Puszkiel
      affiliation:
            name:Université Paul Sabatier
            address:
               name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
               type:PostalAddress
            type:Organization
      name:Gaëlle Noé
      affiliation:
            name:Bicetre Hospital, AP-HP
            address:
               name:Department of Pharmacology and Toxicology, Bicetre Hospital, AP-HP, Kremlin Bicetre, France
               type:PostalAddress
            type:Organization
      name:Audrey Bellesoeur
      affiliation:
            name:CERIA, CARPEM, Cochin University Hospital, APHP
            address:
               name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
               type:PostalAddress
            type:Organization
            name:CERIA, CARPEM, Cochin University Hospital, AP-HP
            address:
               name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
               type:PostalAddress
            type:Organization
      name:Nora Kramkimel
      affiliation:
            name:Cochin University Hospital, AP-HP
            address:
               name:Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
               type:PostalAddress
            type:Organization
      name:Marie-Noëlle Paludetto
      affiliation:
            name:Université Paul Sabatier
            address:
               name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
               type:PostalAddress
            type:Organization
            name:Institut Universitaire du Cancer de Toulouse - Oncopole
            address:
               name:Department of Pharmacy, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
               type:PostalAddress
            type:Organization
      name:Audrey Thomas-Schoemann
      affiliation:
            name:CERIA, CARPEM, Cochin University Hospital, AP-HP
            address:
               name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
               type:PostalAddress
            type:Organization
            name:University Paris Descartes, PRES Sorbonne Paris Cité
            address:
               name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
               type:PostalAddress
            type:Organization
      name:Michel Vidal
      affiliation:
            name:University Paris Descartes, PRES Sorbonne Paris Cité
            address:
               name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
               type:PostalAddress
            type:Organization
            name:CERIA, CARPEM, Cochin University Hospital, AP-HP
            address:
               name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
               type:PostalAddress
            type:Organization
      name:François Goldwasser
      affiliation:
            name:CERIA, CARPEM, Cochin University Hospital, APHP
            address:
               name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
               type:PostalAddress
            type:Organization
      name:Etienne Chatelut
      affiliation:
            name:Université Paul Sabatier
            address:
               name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
               type:PostalAddress
            type:Organization
            name:Institut Universitaire du Cancer de Toulouse - Oncopole
            address:
               name:Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
               type:PostalAddress
            type:Organization
            name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
            address:
               name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
               type:PostalAddress
            type:Organization
      name:Benoit Blanchet
      affiliation:
            name:University Paris Descartes, PRES Sorbonne Paris Cité
            address:
               name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
               type:PostalAddress
            type:Organization
            name:CERIA, CARPEM, Cochin University Hospital, AP-HP
            address:
               name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
               type:PostalAddress
            type:Organization
            name:Groupe de Pharmacologie Clinique Oncologique (GPCO)
            address:
               name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
      name:Department of Pharmacology and Toxicology, Bicetre Hospital, AP-HP, Kremlin Bicetre, France
      name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
      name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
      name:Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
      name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
      name:Department of Pharmacy, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
      name:Multidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
      name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
      name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
      name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
      name:Department of Medical Oncology, CERIA, CARPEM, Cochin University Hospital, APHP, Paris, France
      name:Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France
      name:Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
      name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
      name:UMR8638 CNRS, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
      name:Department of Pharmacokinetics and Pharmacochemistry, CERIA, CARPEM, Cochin University Hospital, AP-HP, Paris, France
      name:Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(242)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.65s.

LINK . SPRINGER . COM {}